Canine EDGE™ DAPPv is a 0.5mL, combined vaccination approved for protection against canine distemper virus, adenovirus type 1 (hepatitis), canine parainfluenza virus, and canine parvovirus.
NOBIVAC EDGE™ DAPPV PROVIDES PROTECTION AGAINST FOUR KNOWN VIRUSES IN A 0.5 ML VACCINE
Canine Distemper Virus, Canine Adenovirus 1 (hepatitis), Canine Parainfluenza Virus, Canine Parvovirus (modified live viruses).
- Protects against all known strains of CPV, including CPV-2c2,3
- High antigenic mass (titer), low passage parvovirus vaccine
- Canine vaccine containing CPV-2b, one of the most prevalent field strains of parvovirus
- Protects against adenovirus type 1 that causes hepatitis in dogs
- Provides disease coverage for commonly spread canine viruses, distemper, adenovirus types 1, parainfluenza and parvovirus in 1 formula
Effective for the vaccination against distemper, adenovirus type 1 (hepatitis), parainfluenza, and parvovirus in one formula.
Recommended for use in healthy dogs 6 weeks of age or older.
Efficacy & Comparisons
D–CANINE DISTEMPER VIRUS (CDV)
- Onderstepoort-type strain in Nobivac® vaccines provides a high level of safety1
A–CANINE ADENOVIRUS TYPE 2 (CAV-2)
- Protection against CAV-1 (hepatitis) without the side effects associated with modified live CAV-1 vaccines4
P–CANINE PARAINFLUENZA VIRUS (CPIV)
- Systemic administration stimulates a strong IgG response1
PROVEN IN AN INDEPENDENT STUDY BY LARSON AND SCHULTZ2
- No clinical signs of disease were seen in Nobivac-vaccinated puppies after challenge with mixed CPV-2b and CPV-2c strains2
- First published data showing protection against CPV-2c challenge2
- All vaccinated puppies were protected from disease
- All control puppies developed disease and 50% died or were euthanized
NOBIVAC EDGE™ DAPPV IS A SAFE CHOICE
- Safety confirmed in 346-dog field study1
- Proven safe across a variety of dog breeds and ages
- Featuring an even higher level of quality due to VacciPure™ filtration
ADMINISTRATION AND DOSAGE
- Subcutaneous injection
- Primary vaccination may begin as early as 6 weeks
- Repeat at 2 to 4 week intervals until the dog is 12 weeks of age
- The need for annual revaccination has not been established
- Available in a 25 x 0.5 mL dose presentation
ALSO AVAILABLE IN OTHER FORMULATIONS
Professional Resources and Educational Materials
Keep your clinic and staff informed and aware of diseases and outbreaks.
In-depth information about canine vaccinations and veterinary best practices.
Use these ready-to-share posts to educate pet parents and drive business to your clinic for preventative care.
A handy guide to protect dogs and prevent the spread of leptospirosis.
1. Data on file, Merck Animal Health.
2. Larson LJ, Schultz RD. Do two current canine parvovirus type 2 and 2b vaccines provide protection against the new type 2c variant? Vet Ther. 2008;9(2):94–101.
3. Schultz RD, Thiel B, Mukhtar E, Sharp P, Larson LJ. Age and long-term protective immunity in dogs and cats. J Comp Pathol. 2010;142 Suppl 1:S102–S108.
4. Greene C, Rupprecht C. Rabies and other lyssavirus infections. In: Greene CE, ed. Infectious Diseases of the Dog and Cat. 3rd ed. St. Louis, MO: Saunders/Elsevier; 2006:167–183.
8. Spibey N, Greenwood NM, Sutton D, Chalmers WS, Tarpey I. Canine parvovirus type 2 vaccine protects against virulent challenge with type 2c virus. Vet Microbiol. 2008;128(1-2) :48-55.
View All Nobivac References